S R Targan

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. ncbi request reprint Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease
    William S Mow
    Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Gastroenterology 126:414-24. 2004
  2. pmc Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study
    Mark S Silverberg
    Mount Sinai Hospital Inflammatory Bowel Disease Group, University of Toronto, 600 University Avenue, Toronto, ON M5G1X5, Canada
    Nat Genet 41:216-20. 2009
  3. pmc Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study
    Matthew L Mundwiler
    Rockford Orthopedic Associates, 324 Roxbury Rd, Rockford, IL 61107, USA
    Arthritis Res Ther 11:R177. 2009
  4. ncbi request reprint Current limitations of IBD treatment: where do we go from here?
    Stephan R Targan
    Cedars Sinai Medical Center, 8700 Beverly Blvd, Suite D4063, Los Angeles, CA 90048, USA
    Ann N Y Acad Sci 1072:1-8. 2006
  5. ncbi request reprint Biology of inflammation in Crohn's disease: mechanisms of action of anti-TNF-a therapy
    S R Targan
    Cedars Sinai Medical Center, Los Angeles, CA, USA
    Can J Gastroenterol 14:13C-16C. 2000
  6. ncbi request reprint CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease
    K A Papadakis
    Department of Medicine, Division of Gastroenterology and Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, UCLA School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Gastroenterology 121:246-54. 2001
  7. pmc Molecular cloning of a Bacteroides caccae TonB-linked outer membrane protein identified by an inflammatory bowel disease marker antibody
    B Wei
    Departments of Pathology and Laboratory Medicine, University of California, Los Angeles, California 90095, USA
    Infect Immun 69:6044-54. 2001
  8. pmc Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics
    E A Vasiliauskas
    Department of Medicine, Cedars Sinai Medical Center and the UCLA School of Medicine, Los Angeles, CA 90048, USA
    Gut 47:487-96. 2000
  9. pmc Increased immune reactivity predicts aggressive complicating Crohn's disease in children
    Marla C Dubinsky
    Department of Pediatrics, IBD Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 6:1105-11. 2008
  10. ncbi request reprint Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens
    Carol J Landers
    Cedars Sinai Medical Center Inflammatory Bowel Disease Center, Los Angeles, California, USA
    Gastroenterology 123:689-99. 2002

Collaborators

Detail Information

Publications106 found, 100 shown here

  1. ncbi request reprint Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease
    William S Mow
    Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Gastroenterology 126:414-24. 2004
    ..Our aim was to determine whether expression of antibodies against Crohn's disease-related bacterial sequence and Escherichia coli outer membrane porin C is associated with distinct phenotypic manifestations...
  2. pmc Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study
    Mark S Silverberg
    Mount Sinai Hospital Inflammatory Bowel Disease Group, University of Toronto, 600 University Avenue, Toronto, ON M5G1X5, Canada
    Nat Genet 41:216-20. 2009
    ..0 x 10(-16), combined OR = 0.66) and at the IL23R locus on chromosome 1p31 (rs11209026, combined P = 1.3 x 10(-8), combined OR = 0.56; rs10889677, combined P = 1.3 x 10(-8), combined OR = 1.29)...
  3. pmc Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study
    Matthew L Mundwiler
    Rockford Orthopedic Associates, 324 Roxbury Rd, Rockford, IL 61107, USA
    Arthritis Res Ther 11:R177. 2009
    ..Because of the overlap between the two conditions, a pilot study was designed to compare the frequency of these antibodies in AS patients compared to normal controls...
  4. ncbi request reprint Current limitations of IBD treatment: where do we go from here?
    Stephan R Targan
    Cedars Sinai Medical Center, 8700 Beverly Blvd, Suite D4063, Los Angeles, CA 90048, USA
    Ann N Y Acad Sci 1072:1-8. 2006
    ....
  5. ncbi request reprint Biology of inflammation in Crohn's disease: mechanisms of action of anti-TNF-a therapy
    S R Targan
    Cedars Sinai Medical Center, Los Angeles, CA, USA
    Can J Gastroenterol 14:13C-16C. 2000
    ..Understanding how TNF-a modulates mucosal Th1 function may lead to the definition of a key feature of Crohn's disease pathogenesis...
  6. ncbi request reprint CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease
    K A Papadakis
    Department of Medicine, Division of Gastroenterology and Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, UCLA School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Gastroenterology 121:246-54. 2001
    ..We characterize the role of TECK and CCR9-expresing lymphocytes in small intestinal Crohn's disease...
  7. pmc Molecular cloning of a Bacteroides caccae TonB-linked outer membrane protein identified by an inflammatory bowel disease marker antibody
    B Wei
    Departments of Pathology and Laboratory Medicine, University of California, Los Angeles, California 90095, USA
    Infect Immun 69:6044-54. 2001
    ..These findings suggest that OmpW may be a target of the IBD-associated immune response and reveal its structural relationship to a bacterial virulence factor of P. gingivalis and periodontal disease...
  8. pmc Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics
    E A Vasiliauskas
    Department of Medicine, Cedars Sinai Medical Center and the UCLA School of Medicine, Los Angeles, CA 90048, USA
    Gut 47:487-96. 2000
    ..Antibodies to Saccharomyces cerevisiae (ASCA) have been demonstrated in the majority of patients with Crohn's disease...
  9. pmc Increased immune reactivity predicts aggressive complicating Crohn's disease in children
    Marla C Dubinsky
    Department of Pediatrics, IBD Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 6:1105-11. 2008
    ..The aims of this study were to determine whether immune responses and/or CARD15 variants are associated with complicated disease phenotypes and predict disease progression...
  10. ncbi request reprint Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens
    Carol J Landers
    Cedars Sinai Medical Center Inflammatory Bowel Disease Center, Los Angeles, California, USA
    Gastroenterology 123:689-99. 2002
    ..Our aim was to determine whether there are heterogeneous responses to these specific antigens...
  11. ncbi request reprint LIGHT is constitutively expressed on T and NK cells in the human gut and can be induced by CD2-mediated signaling
    Offer Cohavy
    Cedars Sinai Inflammatory Bowel Disease Center, Los Angeles, CA 90048, USA
    J Immunol 174:646-53. 2005
    ..Quantitative analysis of LIGHT mRNA in a cohort of inflammatory bowel disease patients indicated elevated expression in biopsies from small bowel and from inflamed sites, implicating LIGHT as a mediator of mucosal inflammation...
  12. ncbi request reprint ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease
    K D Taylor
    Division of Medical Genetics, Cedars Sinai Medical Center, Los Angeles, California, USA
    Gastroenterology 120:1347-55. 2001
    ..The aim of this study was to characterize these subgroups further by antineutrophil cytoplasmic antibody (ANCA) pattern and TNF genotype...
  13. ncbi request reprint Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation
    John L Prehn
    Cedars Sinai Inflammatory Bowel Disease Center, Los Angeles, CA 90048, USA
    Clin Immunol 112:66-77. 2004
    ..Expression of TL1A and its receptor DR3 by lamina propria mononuclear cells (LPMC) could have significant influence on the severity of mucosal inflammation...
  14. ncbi request reprint NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives
    Shane M Devlin
    Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Gastroenterology 132:576-86. 2007
    ..The aim of our study was to determine if defects in innate immunity are similarly associated with increased adaptive immune responses to microbial antigens in Crohn's disease patients...
  15. pmc A novel NOD2/CARD15 haplotype conferring risk for Crohn disease in Ashkenazi Jews
    Kazuhito Sugimura
    Division of Medical Genetics and Inflammatory Bowel Disease Research Center, Department of Medicine, Steven Spielberg Pediatric Research Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Am J Hum Genet 72:509-18. 2003
    ..In Ashkenazi Jews, unrecognized population-specific predisposing factor(s) exist on the 268S-JW1 haplotype at the IBD1 locus. This factor may contribute to the higher risk for CD in Ashkenazi Jews as compared with non-Jews...
  16. pmc Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression
    Marla C Dubinsky
    Department of Pediatrics, Genetics Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Am J Gastroenterol 101:360-7. 2006
    ..We examined the association of immune responses to microbial antigens with disease behavior and prospectively determined the influence of immune reactivity on disease progression in pediatric CD patients...
  17. pmc IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein
    Kathrin S Michelsen
    Inflammatory Bowel Disease Center and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    PLoS ONE 4:e4719. 2009
    ..TL1A and its receptor DR3 are up-regulated during chronic intestinal inflammation in ulcerative colitis and Crohn's disease (CD). TL1A gene haplotypes increase CD susceptibility in Japanese, European, and US cohorts...
  18. pmc TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation
    Hidetoshi Takedatsu
    Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    Gastroenterology 135:552-67. 2008
    ..Expression of TL1A is increased in the mucosa of Crohn's disease patients and murine models of ileitis. The aim of this study was to determine the possible role of TL1A in chronic intestinal inflammation...
  19. pmc Enhanced CBir1-specific innate and adaptive immune responses in Crohn's disease
    Chong Shen
    Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Inflamm Bowel Dis 14:1641-51. 2008
    ..Our aim was to determine whether CBir1 stimulates innate and antigen-specific T-cell responses in CD. We demonstrate that CBir1 enhanced IL-6 and IL-1beta production by peripheral blood (PB) monocytes...
  20. ncbi request reprint Mucosa-specific targets for regulation of IFN-gamma expression: lamina propria T cells use different cis-elements than peripheral blood T cells to regulate transactivation of IFN-gamma expression
    R Gonsky
    Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Immunol 164:1399-407. 2000
    ..This report provides evidence that activation of LPMC results in transactivation of multiple promoter elements regulating IFN-gamma expression distinct from those in PBL...
  21. ncbi request reprint An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy
    M C Dubinsky
    Department of Medicine, Cedars Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
    Inflamm Bowel Dis 7:181-9. 2001
    ..This pilot study evaluated the safety, tolerance, and efficacy of 6-TG in the subgroup of Crohn's disease (CD) patients failing to attain adequate disease control with traditional 6-MP/AZA therapy...
  22. ncbi request reprint HLA class II haplotype associations with inflammatory bowel disease in Jewish (Ashkenazi) and non-Jewish caucasian populations
    E A Trachtenberg
    Children s Hospital Oakland Research Institute, Oakland, CA, USA
    Hum Immunol 61:326-33. 2000
    ....
  23. ncbi request reprint Outcome of cytomegalovirus infections in patients with inflammatory bowel disease
    K A Papadakis
    Division of Gastroenterology, Cedars-Sinai Inflammatory Bowel Disease Center, Los Angeles, California 90048, USA
    Am J Gastroenterol 96:2137-42. 2001
    ..Expedient evaluation, prompt treatment intervention with ganciclovir, and withdrawal of immunosuppressive treatment may avoid complications and mortality. This regimen leads to improvement of the underlying IBD in most patients...
  24. ncbi request reprint TNF-alpha antagonists for the treatment of Crohn's disease
    L Y Kam
    Cedars Sinai Medical Center, Inflammatory Bowel Disease Center, Los Angeles, CA 90048, USA
    Expert Opin Pharmacother 1:615-22. 2000
    ..This review will summarise the key clinical data for each of these categories of TNF-alpha inhibition and discuss the potential economic impact of these new compounds on the cost of CD management...
  25. pmc High-frequency haplotypes in the X chromosome locus TLR8 are associated with both CD and UC in females
    Masayuki Saruta
    Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center and the UCLA School of Medicine, Los Angeles, California 90048, USA
    Inflamm Bowel Dis 15:321-7. 2009
    ..Interestingly, TLR8 is located on the X chromosome and inflammatory bowel disease (IBD) has been associated with abnormalities of the X chromosome. The aim was to test whether TLR8 haplotypes are associated with IBD...
  26. ncbi request reprint CD56 marks an effector T cell subset in the human intestine
    Offer Cohavy
    Cedars Sinai Inflammatory Bowel Disease Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    J Immunol 178:5524-32. 2007
    ..Our findings associate CD56+ T cells with the intestinal immune compartment and suggest a putative effector function in human mucosal immunity...
  27. pmc TLR8-mediated activation of human monocytes inhibits TL1A expression
    Masayuki Saruta
    Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Eur J Immunol 39:2195-202. 2009
    ..Our data demonstrate for the first time a direct interaction between TLR and TL1A signaling pathways. TLR8 activation may be an important, novel pathway for targeted treatment of Th1-mediated diseases, such as CD...
  28. pmc IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease
    Marla C Dubinsky
    Department of Pediatrics, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Inflamm Bowel Dis 13:511-5. 2007
    ..It is unknown whether IL-23R is associated with IBD in children. The aim was to examine the association of IL-23R with susceptibility to IBD in pediatric patients...
  29. pmc Genetic epistasis of IL23/IL17 pathway genes in Crohn's disease
    Dermot P B McGovern
    Medical Genetics Institute and Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Inflamm Bowel Dis 15:883-9. 2009
    ..Genetic variants in the IL23R and IL12B have been associated with CD susceptibility. We investigated 10 genes within the IL23/IL17 pathway in a case-control study of 763 CD cases and 254 healthy controls...
  30. pmc Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease
    Andrew Ippoliti
    Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Inflamm Bowel Dis 16:1279-85. 2010
    ....
  31. doi request reprint Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism
    D Q Shih
    Inflammatory Bowel and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Aliment Pharmacol Ther 36:449-58. 2012
    ..Some IBD patients exhibit dose-limiting preferential 6-MMP production, which may lead to undesired side effects and impact efficacy...
  32. ncbi request reprint Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues
    J L Prehn
    Cedars-Sinai Inflammatory Bowel Disease Center, Los Angeles, California 90048, USA
    J Clin Immunol 21:357-64. 2001
    ..Thalidomide analogues could play a role in treating Crohn's disease and other inflammatory disorders...
  33. ncbi request reprint The role of chemokines and chemokine receptors in mucosal inflammation
    K A Papadakis
    Division of Gastroenterology and Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, California 90048, USA
    Inflamm Bowel Dis 6:303-13. 2000
    ..We also discuss the potential for the use of chemokine or chemokine receptor antagonists as novel therapies for inflammatory bowel disease...
  34. pmc Molecular imaging of murine intestinal inflammation with 2-deoxy-2-[18F]fluoro-D-glucose and positron emission tomography
    Sarah Brewer
    Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California 90095, USA
    Gastroenterology 135:744-55. 2008
    ..However, there is limited understanding of the biologic basis of mucosal FDG uptake...
  35. ncbi request reprint Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease
    Jacob Spivak
    Division of Colon and Rectal Surgery, Department of Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Inflamm Bowel Dis 12:1122-30. 2006
    ..This study examines the association between clinical features and seroreactivity to these microbial and auto-antigens in predicting a clinical response to fecal diversion...
  36. pmc Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells
    David Q Shih
    Inflammatory Bowel Disease Center and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Eur J Immunol 39:3239-50. 2009
    ..Our findings suggest a role for TL1A in pro-inflammatory APC-T cell interactions and implicate TL1A in host responses to enteric microorganisms...
  37. ncbi request reprint High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot study
    William S Mow
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Cedars Sinai Medical Center and UCLA School of Medicine, Los Angeles, California 90048, USA
    Dig Dis Sci 49:1280-6. 2004
    ..Although not statistically significant, these results support further testing to determine whether predominant serum reactivity to certain bacterial antigens may be a marker for efficacious use of antibiotics...
  38. ncbi request reprint High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy
    William S Mow
    Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Clin Gastroenterol Hepatol 2:309-13. 2004
    ..The aim of this study is to evaluate the utility of a TST as an adequate screen for TB exposure in patients with inflammatory bowel disease (IBD)...
  39. ncbi request reprint Definition of a lamina propria T cell responsive state. Enhanced cytokine responsiveness of T cells stimulated through the CD2 pathway
    S R Targan
    Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center, Los Angeles, CA 90048
    J Immunol 154:664-75. 1995
    ....
  40. pmc Linkage of Crohn's disease-related serological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-kappaB activation
    H Takedatsu
    Division of Gastroenterology, Inflammatory Bowel Disease Center, Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Gut 58:60-7. 2009
    ..Our aim was to conduct a linkage study using expression of anti-CBir1, anti-I2, anti-OmpC and ASCA as quantitative traits...
  41. pmc High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis
    P R Fleshner
    Division of Colon and Rectal Surgery, Department of Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Gut 49:671-7. 2001
    ..To date, no preoperative serological predictor of pouchitis has been found...
  42. pmc Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis
    Gil Y Melmed
    Division of Gastroenterology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Dis Colon Rectum 51:100-8. 2008
    ..Preoperative predictors for Crohn's disease post-ileal pouch-anal anastomosis have not been prospectively defined...
  43. ncbi request reprint Immunogenetic phenotypes in inflammatory bowel disease
    Marla C Dubinsky
    Department of Pediatrics, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    World J Gastroenterol 12:3645-50. 2006
    ....
  44. pmc MAGI2 genetic variation and inflammatory bowel disease
    Dermot P B McGovern
    Medical Genetics Institute and Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Inflamm Bowel Dis 15:75-83. 2009
    ..Our aim was to test MAGI2 variants for association with IBD and also their role in determining intermediate hereditary phenotypes defined by antibody production to microbial antigens...
  45. ncbi request reprint Inflammatory bowel disease diagnosis, evaluation and classification: state-of-the art approach
    Stephan R Targan
    Cedars Sinai Inflammatory Bowel Disease Center, Los Angeles, California 90048, USA
    Curr Opin Gastroenterol 23:390-4. 2007
    ..This review will describe the most recent advances and discuss promising pathways for therapeutic discovery...
  46. pmc Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease
    Dermot P B McGovern
    Inflammatory Bowel and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Hum Mol Genet 19:3468-76. 2010
    ..001). These findings strongly implicate this locus in CD susceptibility and highlight the role of the mucus layer in the development of CD...
  47. ncbi request reprint Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial
    Stephan R Targan
    Inflammatory Bowel Disease Center and Division of Gastroenterology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Gastroenterology 132:1672-83. 2007
    ..A randomized placebo-controlled trial evaluated the efficacy of natalizumab induction therapy in patients with Crohn's disease...
  48. pmc Genetic predictors of medically refractory ulcerative colitis
    Talin Haritunians
    Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Inflamm Bowel Dis 16:1830-40. 2010
    ..The aim of this study was to use a genome-wide association study (GWAS) in a well-characterized cohort of UC patients to identify genetic variation that contributes to MR-UC...
  49. ncbi request reprint Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study
    Gil Y Melmed
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California Los Angeles, California, USA
    Clin Gastroenterol Hepatol 5:602-8; quiz 525. 2007
    ..Identification of predictors of a diagnostic change could potentially impact the management of patients with colonic inflammation. Our aim was to characterize clinical and serologic predictors of a change in diagnosis from UC to CD...
  50. ncbi request reprint Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations
    Konstantinos A Papadakis
    Cedars Sinai Inflammatory Bowel Disease Center, Los Angeles, California, USA
    Inflamm Bowel Dis 13:524-30. 2007
    ..We examined the association between anti-CBir1 and clinical phenotypes and NOD2 variants in a large cohort of adult CD patients...
  51. ncbi request reprint Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease
    Stephen A Geller
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Am J Surg Pathol 28:1204-11. 2004
    ..6-TG-related hepatotoxicity, including liver biochemistry value elevations, sinusoidal collagen deposition on electron microscopy, and veno-occlusive disease, have been described related to its use as therapy for neoplastic disease...
  52. pmc IL23R haplotypes provide a large population attributable risk for Crohn's disease
    Kent D Taylor
    Medical Genetics Institute and Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Inflamm Bowel Dis 14:1185-91. 2008
    ..The aim of this work was to estimate the total contribution of this gene to CD risk test using a haplotype approach...
  53. ncbi request reprint CC chemokine receptor 9 expression defines a subset of peripheral blood lymphocytes with mucosal T cell phenotype and Th1 or T-regulatory 1 cytokine profile
    Konstantinos A Papadakis
    Burns and Allen Research Institute and Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
    J Immunol 171:159-65. 2003
    ..Studies on the cytokine profile and Ag specificity of this cell subset could provide important insight into small intestinal immune-mediated diseases and oral tolerance in humans...
  54. ncbi request reprint LIGHT expression by mucosal T cells may regulate IFN-gamma expression in the intestine
    Offer Cohavy
    Cedars Sinai Inflammatory Bowel Disease Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    J Immunol 173:251-8. 2004
    ..Taken together, these findings suggest LIGHT-herpesvirus entry mediator mediated signaling as an important immune regulatory mechanism in mucosal inflammatory responses...
  55. doi request reprint Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease
    Gil Y Melmed
    Department of Medicine, Cedars Sinai Medical Center, University of California, Los Angeles, California 90048, USA
    Am J Gastroenterol 105:148-54. 2010
    ..We aimed to assess the impact of immunosuppression on immune responses to pneumococcal vaccination in patients with IBD...
  56. ncbi request reprint Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease
    William S Mow
    Inflammatory Bowel Disease Center, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 2:31-40. 2004
    ..The aim of this study is to assess the clinical utility of WCE in the evaluation of patients with known or suspected inflammatory bowel disease (IBD)...
  57. pmc Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease
    Marla C Dubinsky
    Department of Pediatrics and Medicine, Inflammatory Bowel Disease Program, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Inflamm Bowel Dis 16:1357-66. 2010
    ..The aim was to test associations of known IBD susceptibility loci and novel "pharmacogenetic" GWAS identified loci with primary nonresponse to anti-TNFalpha in pediatric IBD patients and develop a predictive model of primary nonresponse...
  58. doi request reprint Future biologic targets for IBD: potentials and pitfalls
    Gil Y Melmed
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Cedars Sinai Medical Center, 8635 West 3rd Street, 960 W Los Angeles, CA 90048, USA
    Nat Rev Gastroenterol Hepatol 7:110-7. 2010
    ..Future biologic drug development will benefit from the early identification of subsets of patients who are most likely to respond to therapy by use of biological markers of genetic susceptibility or immunologic susceptibility...
  59. ncbi request reprint Expression and regulation of the chemokine receptor CXCR3 on lymphocytes from normal and inflammatory bowel disease mucosa
    Konstantinos A Papadakis
    Inflammatory Bowel Disease Center and Burns and Allen Research Institute, Los Angeles, CA 90048, USA
    Inflamm Bowel Dis 10:778-88. 2004
    ..Activation-dependent receptor regulation and alteration in receptor-bearing cells, primarily in MLN draining inflamed intestinal tissue, suggest an important role for this T-cell subset in the pathogenesis of human IBD...
  60. ncbi request reprint Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
    Maria T Abreu
    Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Gastroenterology 123:679-88. 2002
    ..NOD2 gene mutations in CD have been described recently and may alter innate immune responses. We hypothesized that NOD2 mutations may be associated with distinct phenotypic expressions of CD...
  61. pmc Genome-wide association identifies multiple ulcerative colitis susceptibility loci
    Dermot P B McGovern
    Inflammatory Bowel and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Nat Genet 42:332-7. 2010
    ..These data implicate approximately 30 loci in ulcerative colitis, thereby providing insight into disease pathogenesis...
  62. ncbi request reprint Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease
    Stephan R Targan
    Cedars Sinai Inflammatory Bowel Disease Center, Los Angeles, California 90048, USA
    Gastroenterology 128:2020-8. 2005
    ....
  63. ncbi request reprint Defects in mucosal immunity leading to ulcerative colitis
    Stephan R Targan
    Division of Gastroenterology, Inflammatory Bowel Disease Center, Immunobiology Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Immunol Rev 206:296-305. 2005
    ..The way in which this response affects the ultimate cascade of inflammatory events has yet to be determined...
  64. doi request reprint A prospective analysis of clinical variables, serologic factors, and outcome of ileal pouch-anal anastomosis in patients with backwash ileitis
    Evan White
    Division of Colon and Rectal Surgery, Cedars Sinai Medical Center, Los Angeles, California, USA
    Dis Colon Rectum 53:987-94. 2010
    ..We prospectively compared the outcomes of ileal pouch-anal anastomosis in colitis patients with backwash ileitis and colitis patients without backwash ileitis...
  65. ncbi request reprint Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes
    Konstantinos A Papadakis
    Burns and Allen Research Institute, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA 90048, USA
    J Immunol 174:4985-90. 2005
    ....
  66. ncbi request reprint Fas activates the JNK pathway in human colonic epithelial cells: lack of a direct role in apoptosis
    M T Abreu-Martin
    Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles 90048, California, USA
    Am J Physiol 276:G599-605. 1999
    ..Fas-Fas ligand interactions in the intestinal mucosa may lead to complex signal transduction cascades and gene regulation that culminate in apoptosis, cytokine secretion, or other novel functions...
  67. ncbi request reprint TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells
    Konstantinos A Papadakis
    Cedars Sinai Inflammatory Bowel Disease Center, Los Angeles, CA 90048, USA
    J Immunol 172:7002-7. 2004
    ..Our data suggest that TL1A/DR3 pathway plays an important role in the augmentation of cytokine-induced IFN-gamma production in T cells and that DR3 expression is differentially regulated by IL-12/IL-18 in T cells and NK cells...
  68. ncbi request reprint Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease
    Ling Mei
    Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Gastroenterology 130:1078-85. 2006
    ..The aim of this study was to determine whether there is familial aggregation and genetic determination of anti-OmpC expression in CD families...
  69. ncbi request reprint Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine
    Marla C Dubinsky
    Department of Medicine, Division of Gastroenterology, Cedars Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
    Am J Gastroenterol 98:1058-63. 2003
    ..The aim of this study was to determine if hypersensitivity reactions to 6-MP/AZA reoccur with 6-TG therapy...
  70. ncbi request reprint Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohn's disease
    Masayuki Saruta
    Inflammatory Bowel Disease Center and Immunobiology Institute, Division of Colorectal Surgery, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Immunol 178:3293-300. 2007
    ..Our data indicate that CCR9(+) T cells in SB CD are proinflammatory and support the rationale for the use of CCR9 antagonists for the treatment of human SB CD...
  71. ncbi request reprint A pilot study of adalimumab in infliximab-allergic patients
    Adrienne Youdim
    Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease Center, Los Angeles, CA 90048, USA
    Inflamm Bowel Dis 10:333-8. 2004
    ..Based on these preliminary data, adalimumab may be a safe and effective substitute for infliximab-allergic patients. Individuals who have been exposed to human antibodies may be sensitized to other human antibodies such as adalimumab...
  72. ncbi request reprint Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis?
    Stefanie J Schluender
    Division of Colon and Rectal Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, 8737 Beverly Boulevard, Suite 101, Los Angeles, California 90048, USA
    Dis Colon Rectum 50:1747-53. 2007
    ..This study was designed to compare short-term complications in patients with ulcerative colitis who were treated with and without infliximab before colectomy...
  73. ncbi request reprint Infliximab in the treatment of medically refractory indeterminate colitis
    K A Papadakis
    Division of Gastroenterology, Cedars Sinai Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Aliment Pharmacol Ther 18:741-7. 2003
    ..To examine the outcome of infliximab intervention in refractory indeterminate colitis...
  74. ncbi request reprint An IFNG SNP with an estrogen-like response element selectively enhances promoter expression in peripheral but not lamina propria T cells
    R Gonsky
    Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Genes Immun 7:342-51. 2006
    ..This is the first report to describe a potential molecular mechanism responsible for selectively controlling IFN-gamma production in LPMC...
  75. ncbi request reprint Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab
    Konstantinos A Papadakis
    Division of Gastroenterology, Department of Medicine, Inflammatory Bowel Disease Center, 8631 W Third Street, Suite 430E, Los Angeles, CA 90048, USA
    Am J Gastroenterol 100:75-9. 2005
    ..The aim of our study was to examine the safety and efficacy of adalimumab (D2E7), a fully humanized anti-TNF-alpha Ab, in CD patients who had experienced an attenuated response to infliximab...
  76. doi request reprint A prospective evaluation of the long-term outcome of ileal pouch-anal anastomosis in patients with inflammatory bowel disease-unclassified and indeterminate colitis
    Zuri A Murrell
    Department of Surgery, Division of Colon and Rectal Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    Dis Colon Rectum 52:872-8. 2009
    ..The aim of this study was to prospectively evaluate the long-term outcome of ileal pouch-anal anastomosis in a closely monitored cohort of patients with ulcerative colitis or indeterminate colitis...
  77. ncbi request reprint Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn
    Eric A Vasiliauskas
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Clin Gastroenterol Hepatol 4:1255-8. 2006
    ..As a result of heightened maternal concern triggered by recent labeling changes, infliximab levels were measured in the newborn of a mother treated with infliximab...
  78. pmc Recent advances in IBD pathogenesis: genetics and immunobiology
    David Q Shih
    Cedars Sinai Inflammatory Bowel Disease Center, 8700 Beverly Boulevard, Suite D4059, Los Angeles, CA 90048, USA
    Curr Gastroenterol Rep 10:568-75. 2008
    ..It focuses on advances in our understanding of IBD from the past year, including advances in genetics and immunobiology...
  79. ncbi request reprint CD2 mediates activation of the IFN-gamma intronic STAT binding region in mucosal T cells
    Rivkah Gonsky
    Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Eur J Immunol 33:1152-62. 2003
    ..Thus, these results indicate that both common as well as unique molecular mechanisms are involved in CD2 signaling and activation of the STAT pathway in LP T cells which are critical for regulation of IFN-gamma expression in the gut...
  80. ncbi request reprint Differences in the management of Crohn's disease among experts and community providers, based on a national survey of sample case vignettes
    E Esrailian
    David Geffen School of Medicine at UCLA, Division of Digestive Diseases, Los Angeles, CA 90095, USA
    Aliment Pharmacol Ther 26:1005-18. 2007
    ..When faced with the same set of facts, healthcare providers often make different diagnoses, employ different tests and prescribe disparate therapies...
  81. ncbi request reprint Identification of a novel bacterial sequence associated with Crohn's disease
    C L Sutton
    Department of Pathology and Laboratory Medicine, University of California, Los Angeles, California, USA
    Gastroenterology 119:23-31. 2000
    ..In this study, representational difference analysis (RDA) was used to isolate DNA segments preferentially abundant in lamina propria mononuclear cells of lesional mucosa vs. adjacent uninvolved mucosa...
  82. ncbi request reprint The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system
    K A Papadakis
    Department of Medicine, Division of Gastroenterology and Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, University of California, Los Angeles School of Medicine, Los Angeles, CA 90048, USA
    J Immunol 165:5069-76. 2000
    ..This regional specialization implies a segregation of small intestinal from colonic immune responses...
  83. ncbi request reprint 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients
    Marla C Dubinsky
    Pediatric Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, 8635 West Third Street, Suite 1165W, Los Angeles, California 90048, USA
    Gastroenterology 125:298-303. 2003
    ..The aim of this study was to describe the association between 6-TG and NRH in IBD...
  84. pmc Ex vivo induction of mRNA in human whole blood as a new platform of drug and dietary supplement development
    Masato Mitsuhashi
    Hitachi Chemical Research Center Inc, Irvine, CA, USA
    Pharm Res 25:1116-24. 2008
    ..This model system was applied to study various fields of drug development...
  85. pmc Immunopathogenesis of inflammatory bowel disease
    David Q Shih
    Cedars Sinai Inflammatory Bowel Disease Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA
    World J Gastroenterol 14:390-400. 2008
    ....
  86. pmc TL1A selectively enhances IL-12/IL-18-induced NK cell cytotoxicity against NK-resistant tumor targets
    Stephanie C Heidemann
    Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center, 8700 Beverly Blvd, D4063, Los Angeles, CA, 90048, USA
    J Clin Immunol 30:531-8. 2010
    ..Its ligand, death domain receptor 3 (DR3), is induced by activation on T and NK cells. Although IL-12/IL-18 induces DR3 expression on most NK cells, addition of TL1A minimally increases IFN-gamma production...
  87. pmc Bacterial flagellin is a dominant antigen in Crohn disease
    Michael J Lodes
    Corixa Corp, Seattle, Washington, USA
    J Clin Invest 113:1296-306. 2004
    ....
  88. ncbi request reprint State of the art: IBD therapy and clinical trials in IBD
    Kim L Isaacs
    University of North Carolina, Chapel Hill, North Carolina, USA
    Inflamm Bowel Dis 11:S3-12. 2005
    ..The number of products under development and continued investigations into the pathogenesis of IBD emphasize the need to expand clinical research efforts in IBD...
  89. ncbi request reprint Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype
    Ian D R Arnott
    Gastrointestinal Unit, University of Edinburgh Department of Medical Sciences, School of Clinical and Molecular Medicine, Western General Hospital, Edinburgh EH4 2XU, UK
    Am J Gastroenterol 99:2376-84. 2004
    ..We aimed to assess the frequency of anti-OmpC, anti-I2, ASCA, and pANCA, in an independent Scottish CD cohort, establish phenotypic associations, and compare with a U.S. cohort...
  90. ncbi request reprint Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease
    Maria T Abreu
    Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease Center, Mount Sinai School of Medicine, New York, NY, USA
    J Clin Gastroenterol 40:55-63. 2006
    ..The aim of this study was to assess the ability of treatment with the TNF-alpha antagonist infliximab to increase bone formation as measured by surrogate markers of bone turnover in patients with active CD...
  91. ncbi request reprint Detection of antisynthetic mannoside antibodies (ASigmaMA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to differential diagnosis, stratification, and prediction
    Peggy Vandewalle-El Khoury
    INSERM, U799, Lille, France
    Am J Gastroenterol 103:949-57. 2008
    ....
  92. pmc TNFSF15 is an ethnic-specific IBD gene
    Yoana Picornell
    Medical Genetics Institute, Cedars Sinai Medical Center Los Angeles, California, USA
    Inflamm Bowel Dis 13:1333-8. 2007
    ..The aim was to confirm the association between TNFSF15 high- and low-risk haplotypes and IBD in a Caucasian population...
  93. doi request reprint Ex vivo simulation of IgG Fc and T-cell receptor functions: an application to inflammatory bowel disease
    Masato Mitsuhashi
    Hitachi Chemical Research Center, Inc, Irvine, California, USA
    Inflamm Bowel Dis 14:1061-7. 2008
    ..Human leukocyte IgG Fc receptors (FcgammaR) and T-cell receptors (TCR) are primary molecules involved in inflammatory and immune pathways...
  94. ncbi request reprint Molecular approaches to the role of the microbiota in inflammatory bowel disease
    Charles O Elson
    Division of Gastroenterology and Hepatology, The University of Alabama Birmingham, 633 Zeigler Research Building, 703 S 19th Street, Birmingham, AL 35294 0007, USA
    Ann N Y Acad Sci 1072:39-51. 2006
    ..Previously unknown microbial flagellins were the dominant cluster of antigens identified. About half of the sera from patients with Crohn's disease have IgG antibodies to these flagellins...
  95. pmc Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis
    John D Rioux
    Université de Montréal and the Montreal Heart Institute, Research Center, 5000 rue Belanger, Montreal, Quebec H1T 1C8, Canada
    Nat Genet 39:596-604. 2007
    ..Together, these findings suggest that autophagy and host cell responses to intracellular microbes are involved in the pathogenesis of Crohn disease...
  96. ncbi request reprint 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease
    Marla C Dubinsky
    Division of Gastroenterology and Genetics, Department of Medicine and Pediatrics, Cedars Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
    Gastroenterology 122:904-15. 2002
    ..The objectives of this study were to determine whether dose escalation optimizes both 6-TGN levels and efficacy in patients failing therapy because of subtherapeutic 6-TGN levels and its effect on TPMT...
  97. ncbi request reprint Biologic therapy of inflammatory bowel disease
    William J Sandborn
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Gastroenterology 122:1592-608. 2002
    ..Based on the early successes of infliximab, CDP571 and natalizumab, it seems certain that biologic therapy will play an important role in the future treatment of inflammatory bowel disease...
  98. ncbi request reprint Anti-CD2O chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's disease
    Konstantinos A Papadakis
    Gastroenterology 124:583. 2003
  99. ncbi request reprint Enhancer role of STAT5 in CD2 activation of IFN-gamma gene expression
    Rivkah Gonsky
    Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    J Immunol 173:6241-7. 2004
    ..This report is the first to describe CD2-mediated activation of STAT5 and supports STAT5 involvement in regulation of IFN-gamma expression...
  100. ncbi request reprint Challenges in IBD Research: updating the scientific agendas
    Charles O Elson
    Division of Gastroenterology, Inflammatory Bowel Disease Center, University of Alabama at Birmingham, USA
    Inflamm Bowel Dis 9:137-53. 2003
  101. ncbi request reprint The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells
    John L Prehn
    Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    J Immunol 178:4033-8. 2007
    ..Furthermore, we demonstrate that TL1A production in monocytes leads to enhancement of T cell responses. The induction of TL1A on APCs via specific pathway stimulation suggests a role for TL1A in Th1 responses to pathogens, and in CD...